A Agilent Technologies Inc.

Agilent Again Named “Global Lighthouse” by World Economic Forum for Manufacturing Innovations

Agilent Technologies Inc. (NYSE: A) today announced the company’s manufacturing facility in Waldbronn, Germany, has been named a Global Lighthouse by the World Economic Forum (WEF) for innovations that boost productivity, output, and quality.

This press release features multimedia. View the full release here:

Agilent's manufacturing facility in Waldbronn, Germany (Photo: Business Wire)

Agilent's manufacturing facility in Waldbronn, Germany (Photo: Business Wire)

The recognition showcases Agilent’s Waldbronn facility as a model of smart manufacturing enabled by Fourth Industrial Revolution (4IR) technologies, such as artificial intelligence and machine learning, robotics, data analytics, and the industrial internet of things (IIoT).

Only 153 manufacturing facilities worldwide have received the Lighthouse distinction from WEF, and Agilent is the sole analytical and clinical laboratory technology company among them. It is the second Agilent facility to be named a Lighthouse, .

Agilent’s Waldbronn facility manufactures high-performance liquid chromatography (HPLC), a technique to separate and detect a wide range of non-volatile organic chemicals. HPLC has numerous applications, from quality control in drug production to the analysis of crime scene samples. The Waldbronn site also produces automated electrophoresis and liquid chromatography supplies.

To earn the Lighthouse designation, the Agilent team rapidly developed, piloted, and scaled smart manufacturing technologies while navigating a period of unprecedented demand and supply chain disruption. The efficiency gains resulted in a 35% increase in manufacturing quality, a 44% increase in productivity, and a 48% increase in output.

“Agilent’s high standards of excellence in our instruments, consumables and services are rooted in our global manufacturing operations,” said President and CEO Mike McMullen. “I am proud of the Agilent team for these impressive results. Our customers benefit from these innovations because they allow us to deliver industry-leading products while quickly and efficiently meeting their needs, even in dynamic, ever-changing conditions.”

Agilent’s Order Fulfillment and Supply Chain division (OFS), which oversees the company’s global manufacturing and supply chain operations, has deployed a variety of 4IR applications at scale, from supply chain reliability prediction and rapid control to predictive cost modeling and digital product simulation.

“When many manufacturers were challenged to fill orders amid pandemic-related supply chain shortages, the Agilent team continued delivering orders on time, increasing customer satisfaction and expanding market share,” said Henrik Ancher-Jensen, head of Agilent’s OFS division. “We have the best team in the business, and this recognition from the World Economic Forum is another testament to their commitment, talent and ingenuity.”

defines 4IR as a leap in technology through intelligent computers that is transforming industry and the economy, just as steam propelled the original Industrial Revolution, electricity powered the second revolution, and early automation and machinery engineered the third industrial revolution.

"Lighthouses are pioneering a path to unprecedented global impact, strategically weaving innovation throughout their expansive network—sculpting both a sustainable future and an era of transformative and lasting change,” said Kiva Allgood, head of WEF’s Centre for Advanced Manufacturing and Supply Chains.

Read more about WEF's Lighthouses, including Agilent's Waldbronn facility, in their new .

About the WEF Global Lighthouse Network

The Global Lighthouse Network is a collaborative platform bringing together forward-thinking manufacturers leading the charge in adopting Fourth Industrial Revolution technologies. Leveraging innovations like artificial intelligence, 3D-printing, and big data analytics, Lighthouses drive efficiency, competitiveness, and transformative business models at scale, fostering economic growth while championing workforce augmentation and environmental protection. Learn more at .

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the . Follow Agilent on and .

EN
14/12/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch